Tazverik treats epithelioid sarcoma, a rare form of soft tissue cancer, by stopping cancer cells from spreading.
The FDA said that half of patients who have the rare cancer have a metastatic form by the time they are diagnosed, meaning it has spread to other parts of their body, which can be life-threatening.
Epizyme, a Massachusetts-based drugmaker, priced Tazverik at $15,500 per month, or $186,000 for a year’s supply, according to Endpoints News.
The FDA is requiring Tazverik to be dispensed with a medication guide that details the risks associated with the treatment, and it is only approved for patients over 16 years.
Read the full news release here.
More articles on pharmacy:
BCBS, Civica Rx create subsidiary to cut generic drug costs
PhRMA spent a record $29M on lobbying in 2019
Former Insys CEO gets 30 months in prison
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
